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ABSTRACT 
Objective: Ritonavir is an antiretroviral drug used for HIV-AIDS treatment. The purpose of this research work was to implement the quality by 
design (QbD) approach in formulation of ritonavir sustained-release pellets by industrially applied extrusion spheronization technique.  
Methods: Pellets were prepared by extrusion spheronization method and evaluated for their physicochemical properties. Initially, on the basis of 
prior knowledge Quality Target Product Profile (QTTP) element was identified and further Critical Quality Attributes (CQA) elements were defined. 
Risk assessment (RA) was done by two tools as failure mode and effect analysis (FMEA) and fishbone diagram (Ishikawa plot). Placket Burman 
design was implemented as a screening design using seven high-risk factors (spheronization speed, spheronization time, extrusion speed, drying 
method, PVP K 30, cross povidone, and solvent). Optimization study was done by 23 
Results: Among all batches obtained in 2
full factorial design with three critical factors as (spheronization 
speed, extrusion speed and PVP K 30). The in vitro drug release was studied in both gastric and intestinal fluids for 12 h using USP Ι apparatus. 
Control space was established for the sustained release pellets.  
3 
Conclusion: We can conclude that; sustained-release pellets of ritonavir were successfully designed using QbD approach.  
full factorial design, batch R7 was found to be effective with carr’s index value of 5.281, percentage yield 
of 69.6%, time required to release 50% drug was 8 h and percent drug release after 12 h was found 83.132 %, R7 batch was selected as optimized 
batch. Statistical analysis showed model terms were significant. 
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INTRODUCTION 
Quality by design (QbD) is the combination of three International 
Conferences of Harmonization Guidelines i.e. (Q8) pharmaceutical 
development, (Q9) quality risk management and (Q10) pharmaceutical 
quality system [1]. QbD is defined as “A systematic approach to 
development that begins with predefined objectives and important 
product and process understanding and process control, based on 
robust supporting science and quality risk management” [2]. The aim of 
QbD is to build the product quality process than the simple test process 
which is based on four important elements: (i) Identification of Quality 
Target Product Profile (QTPP), (ii) Determination of Critical Quality 
Attributes (CQAs) by Critical Process Parameters (CPP), Critical Material 
Attributes (CMA). (iii) Assessment of risk by Failure Mode Effect Analysis 
(FMEA) and Ishikawa Plot (Fishbone Diagram). (iv)Establishment of 
Design Space (DS) and Control Space (CS) [3, 4]. Design Space (DS) is 
defined as ‘The multidimensional combination and interaction of input 
variables and process parameters that have been demonstrated to 
provide assurance of quality” [5, 6]. 
Pellets are defined as spherical, free-flowing granules with a narrow 
size distribution typically varying between 500 to 1500 μm for 
pharmaceutical applications. Sustained release drug delivery system 
in form of pellets formulation comes up with plenty of advantages 
like less gastric irritation, maximized drug absorption, improve drug 
bioavailability, improve flow properties, reduce drug plasma 
fluctuation and reduce potential side effects, Wang et al. [7]. 
Extrusion spheronization technique was used to prepare pellets. The 
critical factor that impact extrusion spheronization are 
spheronization speed, spheronization time, extrusion speed, drying 
method, PVP k30, crosspovidone, solvent, mixing time, 
spheronization load and extruder time all these factors were 
evaluated as per QbD principles, Sirisha et al., Kandukuri et al. [8, 9]. 
Ritonavir is an antiretroviral drug used for HIV-AIDS treatment. 
Sustained-release oral delivery systems are designed to achieve 
therapeutically effective concentration of drug in systemic circulation 
over an extended period of time. Ritonavir is 1,3-thiazol-5-yl methyl N-
[(2S,3S,5S)-3-hydroxy-5-[(2S)-3-methyl-2-{[methyl({[2-(propan-2-yl)-1,3-
thiazol 4yl] methyl})carbamoyl]amino}butanamido]-1,6-diphenyl-hexan-
2-yl]carbamate. Ritonavir is BCS Class ΙΙ drug with half-life of 3-5 h. The 
solubility of drug is poor in gastric pH, Patil et al., Desai et al. [10, 23]. The 
aim of this research work was to apply QbD approach involving risk 
assessment and DoE to ritonavir sustained-release pellets by using an 
extrusion-spheronization method. The study was further continued by 
defining the QTPP and CQAs as preliminary study [11]. Risk assessment 
(FMEA, fishbone diagram) to identify the critical parameter such as CPPs 
(critical process parameters) and CMAs (critical material attributes) 
[12]. Placket-Burman design was implemented as screening design. 23
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factorial design was implemented as optimization design in response 
surface method (RSM) study. DS was established following the obtained 
response surface, control space (CS) was further achieved [13, 14]. 
Material 
Ritonavir was obtained from Mylan lab (Sinner, Nashik), 
Polyoxyethylene 10 lauryl ether as a solubilizer purchased from 
Venus Ethoxyether Pvt. Ltd (Goa, India) Polyvinyl pyrrolidone (PVP 
k-30), Crospovidone, Lactose, Aerosil 200 were obtained from 
Sinhgad College of Pharmacy, (Pune, India) 
Experimental method 
Identification of quality target product profile (QTPP) and to 
define critical quality attributes (CQA) elements 
QTPP elements for ritonavir pellets were identified based on a 
thorough literature survey and prior knowledge. From QTPP 
elements CQA elements were defined. 
Risk assessment 
The fish-bone diagram was considered as to identify the potential 
risks factor of formulation and development, which affects % drug 
release, % yield, and flow properties to identified as the CQAs. Based 
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on prior knowledge, the failure mode and effect analysis (FMEA) 
method were further applied in the initial risk analysis of the 
parameters of the pellets. Each variable was scored in terms of 
severity (S), detectability (D) and probability (P). All the more 
comprehensively, Severity is the wellbeing and viability of the last 
item. Detectability characterized that a disappointment mode can be 
recognized. The last parameter probability is considered as the 
event likelihood or the probability of a disappointment. For each 
hazard, S, D, P scores were increased together to deliver a "Risk 
Priority Number" (RPN). The RPN limit was set at 15;any procedure 
parameter with a RPN 15 was viewed as a potential basic factor 
which sways on CQAs and in item security and viability, while 
factors with a lower RPN can be disposed of from further 
investigation [7, 11].  
Establishment of design space 
Design space was established by using placket-burman design as 
screening design and 23Factorial Design as an optimization design. 
Preparation of ritonavir pellets by extrusion spheronization 
Ritonavir pellets were prepared by the method of extrusion 
spheronization. Ritonavir and various excipients such as PVP K 30, 
lactose, crospovidone and aerosil 200 were mixed in mortar pestle. 
The granulating liquid was added slowly to the powder blend, which 
was then mixed until a homogeneous, cohesive wet mass was 
obtained. The resulting wet mass was extruded at a mesh of size 1.5 
mm. Then spheronization was performed in a spheronizer with a 
rotating chequered plate with cross-hatch geometry (size-3.25 mm) 
for 3 min. Then prepared pellets were air-dried [15]. 
Plackett-Burman design as screening design  
According to the risk assessment results, Plackett-Burman study 
was used to screen 7 critical parameters that may impacts on 
process and formulation development. The sustained release pellets 
which contained ritonavir 200 mg, lactose as diluent which was 55% 
and Aerosil 200 as glidant 1.44% of the amount was kept constant. 7 
critical parameters which are, X1: Spheronization speed; X2: 
spheronization time; X3: Extrusion speed; X4: drying method; X5: PVP 
K30 conc.; X6: Crosspovidone conc.; X7: solvent were evaluated at 
low (-1) and high (+1) levels were. The responses were carr’s index 
(Y1), (Y2) % yield, (Y3) time required to release 50% drug and (Y4) % 
of drug release in 12 h, Sona et al. [13]. 
23
The flow properties of prepared pellets were evaluated by parameters 
like tapped density, carr’s index, Hausner's ratio, angle of repose. 
full factorial design as optimization design 
Depend on the results of the Plackett-Burman screening study. 
Three supercritical parameters were evaluated at 2 levels as high [1] 
and low [-1]. Three critical parameters selected were X1: 
Spheronization speed; X2: Extrusion speed; X3: PVP K30 
concentration. Total 8 batches were prepared. The responses were 
carr’s index (Y1), (Y2) % yield, (Y3) time required to release 50% 
drug and (Y4) % of drug release in 12 h. 
Evaluation of prepared pellets 
Flow properties of pellets 
Particle size and spherical shape 
For determination of particle size of pellets by using Digital Vernier 
caliper was used. About 20 pellets particle from the representative 
sample were randomly taken, and pellets particle size was measured 
and the Average particle size was calculated. 
Percentage yield 
Percentage yield Determine whether the preparation procedure 
chosen for incorporating a drug into the polymers is efficient. The 
raw materials, amount of active compound was weighed and yield 
was determined by weighing the ritonavir pellets and then finding 
out the percentage yield with respect to the weight of the input 
materials, i.e., the weight of drug and polymers used. The formula for 
calculation of % yield is as follows:  
% yield = wt of pellets
wt of drug+wt of polymer
 ×100 
Pellets hardness 
About 20 pellets particle from the representative sample were 
randomly taken, and pellets hardness were measured using digital 
pellets hardness tester. Average hardness was calculated. 
In vitro drug release studies 
The in vitro release of the drug from pellets of all formulation 
batches were performed using USP apparatus type Ι (basket) Lab 
India DS 8000, at 50 rpm. The dissolution media was maintained at 
37±2 °C. “0” size capsules filled with pellets were tested for drug 
release for 12 h in 0.1N HCl (900 ml) by adding polyoxyethylene 10 
lauryl ether for 1st
RESULTS AND DISCUSSION 
 two hrs. Then the dissolution medium was 
changed to phosphate buffer (pH 7.4) by adding 10M of potassium 
di-phosphate 8 ml in 0.1N HCL, and drug release was studied further 
for 12 h. The amount of drug released at each time interval was 
determined by UV spectrometer at 245 nm [21]. 
QTPP of ritonavir and CQAs identification 
Study of QTPP for the formulation 
The QTPP contains a prospective summary of the quality characteristics 
of a drug product that will be ensure the desired quality, safety and 
efficacy of the drug product [12]. QTPP was performed on ritonavir drug 
pellets. QTPP for ritonavir pellets were listed in table 3. 
Risk assessment 
Risk assessment aims to obtain all the potential high impact factors 
which will be subjected to study to establish a product or process 
design space. A fishbone diagram was preformed according to ICH 
Q8 R2, to identify critical process parameters and critical material 
attributes of CQAs that affects the quality of pellets shown in fig. 1. 
The first step in the risk assessment was to systematically gather up 
all the possible factors that could influence product quality. Based on 
the literature data, previous study experiences. After gathering all 
possible factors secondary risk assessment was done by failure 
mode and effect analysis (FMEA) as shown in fig. 2. 
  
Table 1: QTPP for ritonavir sustained-release pellets 
QTPP elements Target  Justification  
Dosage form  Sustained released pellets in capsule Pharmaceutical equivalence requirement 
Route of administration  Oral Pharmaceutical equivalence requirement: Same route of administration 
Dosage strength  200 mg Pharmaceutical equivalence requirement: Same strength 
Stability  At least 24 mo shelf life at room temp Equivalent to or better than RLD shelf-life 
Drug product quality 
attributes 
Physical attributes Pharmaceutical equivalence requirement: Meeting the same compendial or 









Based on scientific prior knowledge and preliminary studies from the initial risk assessment of formulation variables, the flow properties as carr’s 
index, % yield, the time required to release 50% drug and % of drug release in 12 h were selected as critical quality attributes [12]. 
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Fig. 1: Fish-bone diagram illustrating factors that may have an impact on CQAs 
 
 
Fig. 2: RPN score after FMEA risk assessments any variable above the RPN threshold of 15 was considered as a potential risk factors 
 
After risk assessment, further design space was established by using 
placket-burman design as screening design and 23 
Eight batches were formulated (PB1–PB8) containing various ratios 
of lactose and PVP K 30 and crospovidone as shown in table 2. Out of 
all these batches, five batches were excluded from the study as no 
satisfactory results were obtained from them. Then the remaining 
three batches as PB3, PB6 and PB8 were selected for studies. The 
PB3, PB6 and PB8 batches were studied for the particle size analysis, 
bulk density, tapped density, carr’s index and % drug release. The 
results showed that the percent drug release of Ritonavir from PB3, 
PB6 and PB8 formulations under acidic medium after 2h was 
20.191±2.0%, 16.203±1.2%, and 17.481±2.3% respectively and pH 
7.4 after 12 h, 77.467±4.2, 80.467±5.1% and 80.743±5.3% 
respectively as shown in table 3. As PB8 formulation had shown 
better results of dissolution than that of all batches; therefore, PB8 
batch was selected for further studies. Percent drug release after 
12h for batch PB1 to PB8 is shown in fig. 3 and fig. 4. 
Factorial Design 
as an optimization design. 
Plackett-burman design as a screening design 
 
Table 2: Plackett-burman design as a screening design 
Runs X1rpm X2 min X3rpm X4 X5% X6% X7 Y1% Y2% Y3 h Y4% 
PB1 900 10 45 Room 1.5 4.5 Ethanol 10.45±1.2 45.56±3.1 8.30±1.4 57.874±3.1 
PB2 1200 10 45 Oven 3.0 2.5 Ethanol 13.34±0.8 43.78±2.4 9.30±0.8 54.363±2.8 
PB3 1200 20 45 Oven 1.5 4.5 Aq 0.981±0.6 55.78±3.8 7.0±0.7 71.666±4.1 
PB4 900 20 55 Oven 1.5 2.5 Aq 15.87±0.9 56.79±2.9 8.30±1.1 56.786±2.9 
PB5 1200 10 45 Room 1.5 2.5 Aq 10.87±0.2 54.83±1.9 8.30±1.7 66.958±3.5 
PB6 900 20 45 Room 3.0 2.5 Aq 1.042±0.1 50.37±2.1 6.30±2.0 75.795±3.7 
PB7 900 10 55 Oven  3.0 4.5 Ethanol 11.45±1.3 42.73±2.5 8.30±1.1 56.398±2.4 
PB8 1200 20 55 Room 3.0 4.5 Aq 3.714±0.5 61.68±2.6 6.0±0.7 76.832±3.9 
X1: Spheronization speed; X2: spheronization time; X3: Extrusion speed; X4: drying method; X5: PVP K30 conc.; X6: Crosspovidone conc.; X7: solvent. 
The response carr’s index (Y1), (Y2) % yield, (Y3) time required to release 50% drug and (Y4) % of drug release in 12 h. Data are presented as 
mean±SD (n=3) 
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Table 3: Evaluation of three screening batches as PB3, PB6 and PB8 








% D. R 
0.1N HCL (2h) 
% D. R pH7.4 
(12h) 
PB3 1.02 0.706 0.713 0.981±0.1 20.191±2.0 77.467±4.2 
PB6 0.98 0.854 0.863 1.042±0.2 16.203±1.2 80.467±5.1 
PB8 0.97 0.777 0.807 3.714±0.2 17.484±2.3 80.743±5.3 
Data are presented as mean±SD (n=3) 
 
 
Fig. 3: % drug release in 12h (PB1-PB4), data are presented as mean±SD (n=3) 
 
 




full factorial design as optimization design  
3
 
 factorial design studies the response surface methodology (RSM) 
of various variables with help of design expert 8 applied on the 
optimal ritonavir sustained-release pellets using extrusion 
spheronization. Results of the factorial design are shown in table 4. 
Carr’s index (Y1) was found in range of 0.368±0.0 to 5.281±0.2, 
percent yield (Y2) from 48±2.4% to 69.6±3.4%, the time required to 
release 50% drug (Y3) ranges from 6.30 to 8 h and percent drug 
release after 12 h from (Y4) 73.446±4.1% to 83.142±4.19%. The 
statistical analysis results were studied by using Design Expert 8 
software. 3FI model was found to be best fit model and polynomial 
equation shows which variables had the most potential effect on the 
response. Percent drug release for batches R1 to R8 is shown in fig. 5 
and fig. 6. It was differentiated that from all the above batches R7 
batch had shown maximum percentage yield of 69.6±3.4% and 
highest drug release of 83.142±4.19% after 12h. So that R7 batch 
was considered as optimized batch. 
Table 4: 23
 Batches 
full factorial design as an optimization design 
Factors X1 X2 X3 Y1 Y2 Y3 Y4 
X1 X2 X3  Sph. 
speed 
Extru. speed PVP K 30 Carr’s index %yield T50% 12h drug release 
R1 -1 -1 -1 900 45 1.50% 3.195±0.1 54.5±2.1 6.30 79.843±4.2 
R2 1 -1 -1 1400 45 1.50% 0.481±0.0 59.8±3.2 8.0 79.109±3.4 
R3 -1 1 -1 1400 55 1.50% 0.368±0.0 48±2.4 8.0 82.060±4.8 
R4 1 1 -1 1400 55 1.50% 0.651±0.1 65.8±3.1 7.30 76.117±1.4 
R5 -1 -1 1 900 45 3.00% 2.098±0.2 49.8±3.0 7.0 81.897±5.3 
R6 1 -1 1 900 45 3.00% 4.361±0.4 67.85±2.9 8.0 80.781±5.1 
R7 -1 1 1 900 55 3.00% 5.281±0.2 69.6±3.4 8.0 83.142±4.9 
R8 1 1 1 1400 55 3.00% 3.541±0.3 59.5±2.4 8.30 73.446±4.1 
X1: Spheronization speed; X2:Extrusion speed; X3:PVP K30 conc. The response carr’s index (Y1), (Y2) % yield, (Y3) time required to release 50% drug 
and (Y4) % of drug release in 12 h. Data are presented as mean±SD (n=3) 
Mandlik et al. 
Int J App Pharm, Vol 12, Issue 1, 2020, 139-146 
143 
 
Fig. 5: Percent drug release in 12 h (R1-R4), data are presented as mean±SD (n=3) 
 
 
Fig. 6: Percent drug release in 12 h (R5-R8), data are presented as mean±SD (n=3) 
 
Statistical analysis for Y1, Y2, Y3 and Y4  
Statistical analysis of the design was carried out by using registered 
Design Expert 8 (Stat Ease Inc. Minneapolis USA). The obtained data 
were fitted in the Design Expert Software to analyze different 
statistical parameters. The statistical analysis model explaining the 
effect of various factors on response surface methodology RSM of 
output variables like carr’s index, % yield, T50% (time required to 
release 50% of the drug) and % drug release in 12 h. The optimum 
preparations were selected. Optimum preparation was picked by the 
critical evaluation. The criteria for selection of optimum preparations 
is primarily based on maximum drug release at 12 hr. 3FI model is 
studied for Y1, Y2, Y3 and Y4 in detail to established the DS. 
For Y1 (carr’s index) the 3 factor interaction (3FI) was found to be 
best fit model and polynominal equation is given below. 
Y1 (Carr’s index) =+2.50-0.24X1-0.037X2+1.32X3-
0.13X1X2+0.37X1X3+0.63X2X3-0.88X1X2X3 are in 3D plot in fig. 7. 
Y2 (percentage yield) =+59.36+3.88*X1+1.37*X2+2.33*X3-1.96*X1X2-
1.89*X1X3+*X2X3-5.08*X1X2X3 is given in 3D graph fig. 8. 
It shows that X3 (PVP K30) has shown a positive effect on and X1 
(Spheronization speed) shown negative effect flow properties of 
pellets that is carr’s index. Increases with interaction with X3X1 
spheronization speed and PVP K30 give a good carr’s index and have 
a positive impact on the flow properties of pellets shown in fig. 7. 
The response surface for % yield was studied by polynomial 
equation by 3FI interaction it was seen that increasing the X1 and X2 
i.e. spheronization speed and extrusion speed gives good and 
positive impact on % yield up to 69 %. The DS was achieved within 
the value. As shown in fig. 8. 3D plot. 
 
 
Fig. 7: 3D response surface plot for Carr’s index (Y1) 
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Fig. 8: 3D response surface plot for percentage yield (Y2) 
 
Y3 (T50%) =+7.61+0.29*X1+0.29*X2+0.21*X3-0.39*X1X2+0.038*X2X3+ 
0.21*X1X2X3 given in 3D graph fig. 9 
Y4 (Drug release 12h) =+79.55+2.19*X1-0.86*X2+0.27*X3-1.72*X1X2-
0.52*-0.66*X2X3-0.42*X1X2X3 given in 3D graph fig. 10 
 
 
Fig. 9: 3D response surface plot for time required to release 50% drug (Y3) 
 
 
Fig. 10: 3D response surface plot for percent drug release (Y4) 
 
Based on the response surface model. For the third response, all three 
factors had shown positive effect on response. As the binder 
concentration increases the time required for release the 50% drug is 
improved plot as shown in fig. 9. For the response percent drug 
release. Binder concentration PVP K30 has positive effect on drug 
release. As the PVP K30 increases, the dissolution also improved. 
Extrusion speed and spheronization speed had shown same positive 
impact on the dissolution profile. The DS was achieved within the 
value as shown in fig. 10. The drug release was achieved at the range 
of 83.142±4.19 in 3D plot. The Y1 was found to be 5.281±0.2 as a good 
carr’s index for batch R7, percentage yield found 69.6±3.4%, time 
required to release 50% drug found to be 8 h, percent drug release 
was found 83.142±4.9 % so from all the four responses batch R7 was 
found to be best batch and selected as optimized batch.  
Development of control strategy for ritonavir sustained-release 
pellets 
The process control was determined on the carr’s index (Y1<10), 
%yield (Y2>70%), T50% (Y3>8 h) and % drug release (>80%). 
According to the result of Plackett-Burman design and 23 factorial 
design, the final control space was defined in detail in table 5. 
Spheronization speed (1200rpm), Spheronization time (20 min), 
extrusion speed (55rpm) and PVP K 30 (3.0%). In order to define 
the final control space, one formulation parameter was range to the 
final control space that is R7. Design space includes the control 
strategy. in which three factors were performed in 23 factorial 
design as final process for pellets by extrusion spheronization which 
are CPPs and CMAs from CQAs [12, 22]. 
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Table 5: Control strategy for ritonavir sustained released pellets 




Justification for range Purpose of control 
 
Critical Material Attributes 
Povidone K-30 Binder % 3.0%-7.0% Optimization range studied To ensure batch to batch consistency 
Critical Process Parameters 
Pellets Process 
Parameter 
Extrusion speed Time: 10 min 
Speed: 55rpm 
Optimization range studied To ensure all pellets CQAs (Yield, flow 
properties, Dissolution) are met consistently 
Spheronization 
speed 
Time: 20 min 
Speed: 1400 rpm 
Mixing Time: 15 min 
 
Drying Process Parameters 
Drying parameter 
of Pellets 
Hot oven 110 °C Optimization range studied 
 
To ensure batch to batch reproducibility for PSD 
of pellets, flowability, Dissolution 
Drying time 10 min–20 min Optimization range studied To ensure batch to batch reproducibility pellets 
properties like PSD 
Extrusion spheronization pellets In-Process Controls 
Individual weight 500.0 mg±5.0 %  Parameter fixed based on lab 
scale development experience 
To ensure all pellets CQAs (Drug content, 




Limits: 1 mm±0.5 mm 
Friability NMT 1.0 % 
Spheronization speed 1400rmp 
Extrusion speed 55rmp 
 
CONCLUSION 
QbD is an essential part of the modern approach to pharmaceutical 
quality. This current study demonstrated how QbD approach can be 
applied toward the development of a formulation of ritonavir SR 
pellets. This study teaches the use of QbD including an emphasis on 
the importance of the target product quality profile in a quantitative 
performance target for QbD. Fish-bone diagram and FMEA analysis 
were used to identify critical formulation and process parameters 
that affect ritonavir sustained-release pellets product quality. Next, 
the Plackett-Burman and 23 factorial design were used for screening 
the significant factors and optimizing the variables range, 
respectively. The final aim of this approach to achieve Design space. 
Lastly control strategy was defined. It could be concluded that 
sustained-release pellets were successfully designed using QbD 
approach. 
AUTHORS CONTRIBUTIONS 
All the authors have contributed equally. 
CONFLICTS OF INTERESTS 
The authors declare no conflicts of interest. 
REFERENCES 
1. Sonar G, Rawat S. Optimization of pantoprazole enteric pellets 
coating process by qbd: effect of coating process variables on 
the intermediate quality of the product and scale-up. Int J 
Pharm Pharm Sci 2015;7:80-7. 
2. Patil AS, Pethe AM. Quality by design (Qbd): a new concept for 
the development of quality pharmaceuticals. Int J Qual Assur 
2013;4:13-9. 
3. Gawade A, Chemate S, Kuchekar A. Pharmaceutical quality by 
design: a new approach in product development. Res Rev: J 
Pharm Pharm Sci 2013;2:1-8. 
4. Roy S. Quality by design: a holistic concept of building quality 
in pharmaceuticals. Int J Pharm Biomed Res 2012;3:100-8. 
5. Lawrence XY. Pharmaceutical quality by design: product and 
process development, understanding, and control. Pharm Res 
2008;25:781-91. 
6. Jain S. Quality by design (Qbd): a comprehensive 
understanding of implementation and challenges in 
pharmaceuticals development. Int J Pharm Pharm Sci 
2014;6:29-35. 
7. Wang J, Kan S, Chen T, Liu J. Application of quality by design 
(Qbd) to the formulation and processing of naproxen pellets by 
extrusion–spheronization. Pharm Dev Technol 2015;20:246-
56. 
8. Sirisha VR, Sri KY, Suresh K, Reddy Gk, Devanna N. A review of 
pellets and pelletization process-a multiparticulate drug 
delivery system. Int J Pharm Sci Res 2013;4:2145. 
9. Kandukuri JM, Allenki V, Eaga Cm, Keshetty V, Jannu KK. 
Pelletization techniques for oral drug delivery. Int J Pharm Sci 
Res 2009;1:63-70. 
10. Patil KJ, Sarode SM. Formulation and evaluation of sustained-
release tablet of ritonavir. World J Pharm Pharm Sci 
2014;3:854-69. 
11. Kaljevic O, Djuris J, Djuric Z, Ibric S. Application of failure mode 
and effects analysis in quality by design approach for 
formulation of carvedilol compression coated tablets. J Drug 
Delivery Sci Technol 2016;32:56-63. 
12. Us Food and Drug Administration. Quality By Design For Ands: 
An Example For Modified-Release Dosage Forms; 2011. 
13. Sona PS, C Muthulingam, G Geetha. Preparation of pellets of 
bosentan by extrusion spheronizationscreening study of 
process parameters by plackett-burman design. Int J Pharm 
Life Sci 2012;2:88-97. 
14. Dua S, Mahant S, Tiwari R. Influence of process and formulation 
variables on physical properties of the pellets using a 23 
factorial design. Int J Pharm Sci Rev Res 2011;7:47-50. 
15. Puranik PK, Khan FM. Formulation and evaluation of 
aceclofenac loaded sr matrix pellets: extrusion spheronization. 
Int J Pharm Pharm Sci 2013;5:781-9. 
16. Upasani A, Kshirsagar S, Bhalekar M. Design and optimization 
of sustained release matrix tablet of opipramol hcl by using 
quality by design approach. Asian J Pharm Clin Res 2014;7:224-
34. 
17. Kumar KS, Bhowmik D, Srivastava S, Paswan S, Dutta As. 
Sustained-release drug delivery system potential. Pharma 
Innovation 2012;1:48-60. 
18. Zameeruddin M, Namdev H, Jadhav SB, Kadam VS, Bharkad VB, 
Anil B. Recent advances of sustained-release oral drug delivery 
system: a review. Int J Pharm Sci Biomed Sci 2014;3:1479-89.  
19. Lavanya K, Senthil V, Rathi V. Pelletization technology: a quick 
review. Int J Pharm Sci Res 2011;2:1337. 
20. Jezerska L, Zajonc O, Vyletelek J, Zegzulka J. Mechanical 
material properties effect on pelletization. Wood Res 
2016;61:307-20. 
21. Singh G, Pai RS, Devi VK. Optimization of pellets containing 
solid dispersion prepared by extrusion/spheronization using 
central composite design and desirability function. J Young 
Pharm 2012;4:146-56. 
Mandlik et al. 
Int J App Pharm, Vol 12, Issue 1, 2020, 139-146 
146 
22. S SY, V SS, N KR. Formulation optimization of promethazine 
theoclate immediate release pellets by using the extrusion-
spheronization technique. Int J Appl Pharm 2018;10:30-5. 
23. Desai S, J Disouza, K Musle, H Avinash. Solubility enhancement 
of ritonavir by hot melt extrusion. Int J Pharm Pharm Sci 
2016;8:309-12.
 
